Unveiling the mechanism of action of acylated temporin L analogues against multidrug-resistant Candida albicans

References

• Domán M, Bányai K. COVID-19-associated fungal infections: an urgent need for alternative therapeutic approach.? Front Microbiol. 2022;13:919501.
   PubMed Web of Science ®Google Scholar
• Ré ACS, Martins JF, Cunha-Filho M, Gelfuso GM, Aires CP, Gratieri T. New perspectives on the topical management of recurrent candidiasis. Drug Deliv Transl Res. 2021;11(4):1568–1585.
   PubMed Web of Science ®Google Scholar
• Mukaremera L, Lee KK, Mora-Montes HM, Gow NAR. Candida albicans yeast, pseudohyphal, and hyphal morphogenesis differentially affects immune recognition. Front Immunol. 2017;8(1):629.
   PubMedGoogle Scholar
• de Cássia Orlandi Sardi J, de Souza Pitangui N, Gullo FG, Fusco-Almeida AM, Mendes-Giannini MJS. A mini review of Candida species in hospital infection: epidemiology, virulence factor and drugs resistance and prophylaxis. Trop. Med. Surg. 2013;1:5.
   Google Scholar
• Nucci M, Queiroz-Telles F, Tobón AM, Restrepo A, Colombo AL. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis. 2010;51(5):561–570.
   PubMed Web of Science ®Google Scholar
• Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, Kotris I, Škrlec I. Candida albicans-the virulence factors and clinical manifestations of infection. JoF. 2021;7(2):79.
   Google Scholar
• Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev. 2003;67(3):400–428, table of contents.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and mechanisms of antifungal resistance. Antibiotics (Basel. 2020;9(6):312.
   PubMed Web of Science ®Google Scholar
• Danby CS, Boikov D, Rautemaa-Richardson R, Sobel JD. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Antimicrob Agents Chemother. 2012;56(3):1403–1406.
   PubMed Web of Science ®Google Scholar
• Zhang MR, Zhao F, Wang S, Lv S, Mou Y, Yao CL, Zhou Y, Li FQ. Molecular mechanism of azoles resistant Candida albicans in a patient with chronic mucocutaneous candidiasis. BMC Infect. Dis. 2020;20:126.
   PubMed Web of Science ®Google Scholar
• Tverdek FP, Kofteridis D, Kontoyiannis DP. Antifungal agents and liver toxicity: a complex interaction. Expert Rev anti Infect Ther. 2016;14(8):765–776.
   PubMed Web of Science ®Google Scholar
• Buda De Cesare G, Cristy SA, Garsin DA, Lorenz MC. Antimicrobial peptides: a new frontier in antifungal therapy. mBio. 2020;11(6):20.
   Web of Science ®Google Scholar
• Wang J, Dou X, Song J, Lyu Y, Zhu X, Xu L, Li W, Shan A. Antimicrobial peptides: promising alternatives in the post feeding antibiotic era. Med Res Rev. 2019;39(3):831–859.
   PubMed Web of Science ®Google Scholar
• Falanga A, Maione A, La Pietra A, de Alteriis E, Vitale S, Bellavita R, Carotenuto R, Turrà D, Galdiero S, Galdiero E, et al. Competitiveness during dual-species biofilm formation of Fusarium oxysporum and Candida albicans and a novel treatment strategy. Pharmaceutics. 2022;14(6):1167.
   PubMed Web of Science ®Google Scholar
• Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev. 2006;19(3):491–511,
   PubMed Web of Science ®Google Scholar
• Maione A, Bellavita R, de Alteriis E. d, Galdiero S, Albarano L, La Pietra AL, Guida M, Parrilli E, D’Angelo C, Galdiero E, et al. A. WMR peptide as antifungal and antibiofilm against albicans and non-albicans Candida species: shreds of evidence on the mechanism of action. IJMS. 2022;23(4):2151.
   Google Scholar
• Silva ARP, Guimarães MS, Rabelo J, Belén LH, Perecin CJ, Farías JG, Santos JHPM, Rangel-Yagui CO. CO. Recent advances in the design of antimicrobial peptide conjugates. J Mater Chem B. 2022;10(19):3587–3600.
   PubMed Web of Science ®Google Scholar
• Romero SM, Cardillo AB, Martínez Ceron MC, Camperi SA, Giudicessi SL. Temporins: an approach of potential pharmaceutic candidates. Surg Infect. 2020;21(4):309–322.
   PubMed Web of Science ®Google Scholar
• Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni ML, et al. Broad-Spectrum antiviral activity of the amphibian antimicrobial peptide Temporin L and its analogs. IJMS. 2022;23(4):2060.
   Google Scholar
• Mangoni ML, Grazia AD, Cappiello F, Casciaro B, Luca V. Naturally occurring peptides from Rana temporaria: antimicrobial properties and more. Curr Top Med Chem. 2016;16(1):54–64.
   PubMed Web of Science ®Google Scholar
• Bellavita R, Maione A, Merlino F, Siciliano A, Dardano P, De Stefano L, Galdiero S, Galdiero E, Grieco P, Falanga A. Antifungal and antibiofilm activity of cyclic Temporin L peptide analogues against albicans and non-albicans Candida species. Pharmaceutics. 2022;14(2):454.
   PubMed Web of Science ®Google Scholar
• Bellavita R, Casciaro B, Di Maro S, Brancaccio D, Carotenuto A, Falanga A, Cappiello F, Buommino E, Galdiero S, Novellino E, et al. First-in-Class cyclic Temporin L analogue: design, synthesis, and antimicrobial assessment. J Med Chem. 2021;64(15):11675–11694.
   PubMed Web of Science ®Google Scholar
• Merlino F, Carotenuto A, Casciaro B, Martora F, Loffredo MR, Di Grazia A, Yousif AM, Brancaccio D, Palomba L, Novellino E, et al. Glycine-replaced derivatives of [Pro3,Dleu9]TL, a temporin L analogue: evaluation of antimicrobial, cytotoxic and hemolytic activities. Eur J Med Chem. 2017;139:750–761.
   PubMed Web of Science ®Google Scholar
• Bellavita R, Vollaro A, Catania MR, Merlino F, De Martino L, Nocera FP, Della Greca M, Lembo F, Grieco P, Buommino E. Novel antimicrobial peptide from Temporin L in the treatment of Staphylococcus Pseudointermedius and Malassezia Pachydermatis in polymicrobial inter-kingdom infection. Antibiotics (Basel. 2020;9(9):530.
   PubMedGoogle Scholar
• Bellavita R, Raucci F, Merlino F, Piccolo M, Ferraro MG, Irace C, Santamaria R, Iqbal AJ, Novellino E, Grieco P, et al. Temporin L-derived peptide as a regulator of the acute inflammatory response in zymosan-induced peritonitis. Biomed Pharmacother. 2020;123:109788–109788.
   PubMed Web of Science ®Google Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919–934.
   PubMed Web of Science ®Google Scholar
• de Alteriis E, Maione A, Falanga A, Bellavita R, Galdiero S, Albarano L, Salvatore MM, Galdiero E, Guida M. Activity of free and liposome-encapsulated essential oil from Lavandula angustifolia against persister-derived biofilm of Candida auris. Antibiotics. 2021;11(1):26.
   Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
   PubMed Web of Science ®Google Scholar
• Bellavita R, Falanga A, Buommino E, Merlino F, Casciaro B, Cappiello F, Mangoni ML, Novellino E, Catania MR, Paolillo R, et al. Novel Temporin L antimicrobial peptides: promoting self-assembling by lipidic tags to tackle superbugs. J Enzyme Inhib Med Chem. 2020;35:751–1764.
   Web of Science ®Google Scholar
• Roscetto E, Bellavita R, Paolillo R, Merlino F, Molfetta N, Grieco P, Buommino E, Catania MR. Antimicrobial activity of a lipidated Temporin L analogue against carbapenemase-producing Klebsiella pneumoniae clinical isolates. Antibiotics. 2021;10(11):1312.
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance standards for antifungal susceptibility testing of yeasts. M60 – 2nd Ed. Pennsylvania (US): Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing - EUCAST. Clinical breakpoints for fungi (Candida and Aspergillus species). Available from: https://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals. v. 10.0, accessed on 4 April 2022.
   Google Scholar
• Merlino F, Tomassi S, Yousif AM, Messere A, Marinelli L, Grieco P, Novellino E, Cosconati S, Maro D. S. Boosting Fmoc solid-phase peptide synthesis by ultrasonication. Org Lett. 2019;21(16):6378–6382.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27 – 4th Ed. Pennsylvania (US): Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• Varma SR, Sivaprakasam TO, Mishra A, Prabhu S, M R, P R. Imiquimod-induced psoriasis-like inflammation in differentiated human keratinocytes: its evaluation using curcumin. Eur J Pharmacol. 2017;813:33–41.
   PubMed Web of Science ®Google Scholar
• Del Genio V, Falanga A, Allard-Vannier E, Hervé-Aubert K, Leone M, Bellavita R, Uzbekov R, Chourpa I, Galdiero S. Design and validation of nanofibers made of self-assembled peptides to become multifunctional stimuli-sensitive nano-vectors of anticancer drug doxorubicin. Pharmaceutics. 2022;14(8):1544.
   PubMed Web of Science ®Google Scholar
• Xue C, Lin TY, Chang D, Guo Z. Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R Soc Open Sci. 2017;4(1):160696.
   PubMed Web of Science ®Google Scholar
• Bolen EJ, Holloway PW. Quenching of tryptophan fluorescence by brominated phospholipid. Biochemistry. 1990;29(41):9638–9643.
   PubMed Web of Science ®Google Scholar
• De Kroon AI, Soekarjo MW, De Gier J, De Kruijff B. The role of charge and hydrophobicity in peptide-lipid interaction: a comparative study based on tryptophan fluorescence measurements combined with the use of aqueous and hydrophobic quenchers. Biochemistry. 1990;29(36):8229–8240.
   PubMed Web of Science ®Google Scholar
• Yousif AM, Ingangi V, Merlino F, Brancaccio D, Minopoli M, Bellavita R, Novellino E, Carriero MV, Carotenuto A, Grieco P. Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration. Eur J Med Chem. 2018;143:348–360.
   PubMed Web of Science ®Google Scholar
• Wuthrich K. NMR of proteins and nucleic acids. New York: Wiley; 1986.
   Google Scholar
• Güntert P, Qian YQ, Otting G, Müller M, Gehring W, Wüthrich K. Structure determination of the Antp (C39––S) homeodomain from nuclear magnetic resonance data in solution using a novel strategy for the structure calculation with the programs DIANA, CALIBA, HABAS and GLOMSA. J Mol Biol. 1991;217(3):531–540.
   PubMed Web of Science ®Google Scholar
• Thevissen K, Terras FR, Broekaert WF. Permeabilization of fungal membranes by plant defensins inhibits fungal growth. Appl Environ Microbiol. 1999;65(12):5451–5458.
   PubMed Web of Science ®Google Scholar
• Ruissen AL, Groenink J, Helmerhorst EJ, Walgreen-Weterings E, Van’t Hof W, Veerman EC, Nieuw Amerongen AV. Nieuw Amerongen AV. effects of histatin 5 and derived peptides on Candida albicans. Biochem J. 2001;356(Pt 2):361–368.
   PubMedGoogle Scholar
• Bugli F, Massaro F, Buonocore F, Saraceni PR, Borocci S, Ceccacci F, Bombelli C, Di Vito M, Marchitiello R, Mariotti M, et al. Design and characterization of myristoylated and non-myristoylated peptides effective against Candida spp. clinical isolates. IJMS. 2022;23(4):2164.
   Google Scholar
• Malina A, Shai Y. Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem J. 2005;390(Pt 3):695–702.
   PubMedGoogle Scholar
• Wishart DS, Sykes BD, Richards FM. Relationship between nuclear magnetic resonance chemical shift and protein secondary structure. J Mol Biol. 1991;222(2):311–333.
   PubMed Web of Science ®Google Scholar
• Guntert P. Automated NMR structure calculation with CYANA. Methods Mol. Biol. 2004;278:353–378.
   PubMedGoogle Scholar
• Brown LR, Bosch C, Wuthrich K. Location and orientation relative to the micelle surface for glucagon in mixed micelles with dodecylphosphocholine: EPR and NMR studies. Biochim. Biophys. Acta. 1981;642(2):296–312.
   PubMedGoogle Scholar
• Hancock RE, Rozek A. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett. 2002;206(2):143–149.
   PubMed Web of Science ®Google Scholar
• Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta. 1999;1462(1–2):55–70.
   PubMed Web of Science ®Google Scholar
• Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 2019;25(7):792–798.
   PubMed Web of Science ®Google Scholar
• Liu S, Hou Y, Chen X, Gao Y, Li H, Sun S. Combination of fluconazole with non-antifungal agents: a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery. Int J Antimicrob Agents. 2014;43(5):395–402.
   PubMed Web of Science ®Google Scholar